ดูเหมือนว่ามีข้อผิดพลาดเกิดขึ้นขณะกำลังโหลดหน้าเพจนี้.
ทีมงานของเราได้รับแจ้งแล้วแต่กรุณาติดต่อเราด้วยการใช้ วิจิทบริการสนับสนุนทางอีเมล หากปัญหายังคงมีอยู่
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | 9.1x - 10.0x | 9.5x |
| Selected Fwd EBITDA Multiple | 4.6x - 5.1x | 4.9x |
| Fair Value | ₩6,651 - ₩7,351 | ₩7,001 |
| Upside | 22.9% - 35.9% | 29.4% |
| Benchmarks | Ticker | Full Ticker |
| JW Lifescience Corporation | A234080 | KOSE:A234080 |
| Kyung Dong Pharmaceutical Co., Ltd. | A011040 | KOSDAQ:A011040 |
| Ahn-Gook Pharmaceutical Co., Ltd. | A001540 | KOSDAQ:A001540 |
| Dongwha Pharm.Co.,Ltd | A000020 | KOSE:A000020 |
| Ilyang Pharmaceutical Co.,Ltd | A007570 | KOSE:A007570 |
| DongKoo Bio & Pharma Co., Ltd. | A006620 | KOSDAQ:A006620 |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| A234080 | A011040 | A001540 | A000020 | A007570 | A006620 | ||
| KOSE:A234080 | KOSDAQ:A011040 | KOSDAQ:A001540 | KOSE:A000020 | KOSE:A007570 | KOSDAQ:A006620 | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | 4.5% | -23.9% | 18.0% | 9.5% | -13.3% | NM- | |
| 3Y CAGR | 7.4% | -29.3% | 61.3% | -1.5% | -7.6% | 14.8% | |
| Latest Twelve Months | 11.2% | 142.1% | 42.6% | 1.6% | -26.5% | -3.3% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | 24.1% | 6.7% | 4.4% | 10.8% | 10.7% | 9.4% | |
| Prior Fiscal Year | 22.4% | -11.7% | 4.3% | 9.0% | 10.6% | 9.6% | |
| Latest Fiscal Year | 23.2% | 4.1% | 5.3% | 7.1% | 7.7% | 8.0% | |
| Latest Twelve Months | 23.2% | 4.1% | 5.3% | 7.1% | 7.7% | 8.0% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 1.04x | 0.47x | 0.35x | 0.40x | 0.90x | 0.59x | |
| EV / LTM EBITDA | 4.5x | 11.4x | 6.7x | 5.6x | 11.7x | 7.3x | |
| EV / LTM EBIT | 6.5x | 34.9x | 14.3x | 13.9x | 22.1x | 11.5x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | 4.5x | 6.7x | 11.7x | ||||
| Historical EV / LTM EBITDA | 5.9x | 7.4x | 17.8x | ||||
| Selected EV / LTM EBITDA | 9.1x | 9.5x | 10.0x | ||||
| (x) LTM EBITDA | 19,964 | 19,964 | 19,964 | ||||
| (=) Implied Enterprise Value | 180,826 | 190,343 | 199,860 | ||||
| (-) Non-shareholder Claims * | (88) | (88) | (88) | ||||
| (=) Equity Value | 180,738 | 190,255 | 199,772 | ||||
| (/) Shares Outstanding | 27.0 | 27.0 | 27.0 | ||||
| Implied Value Range | 6,683.57 | 7,035.51 | 7,387.45 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 6,683.57 | 7,035.51 | 7,387.45 | 5,410.00 | |||
| Upside / (Downside) | 23.5% | 30.0% | 36.6% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A234080 | A011040 | A001540 | A000020 | A007570 | A006620 | |
| Enterprise Value | 231,246 | 91,514 | 95,613 | 186,365 | 242,875 | 146,386 | |
| (+) Cash & Short Term Investments | 9,622 | 30,913 | 29,738 | 43,497 | 12,790 | 36,250 | |
| (+) Investments & Other | 559 | 69,556 | 28,043 | 65,942 | 43,510 | 50,419 | |
| (-) Debt | (69,238) | (38,677) | (77,724) | (96,989) | (107,681) | (86,641) | |
| (-) Other Liabilities | 0 | (276) | 932 | (28,304) | (3,582) | (116) | |
| (-) Preferred Stock | 0 | 0 | 0 | (1,154) | (1,113) | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 172,188 | 153,029 | 76,603 | 169,357 | 186,799 | 146,298 | |
| (/) Shares Outstanding | 15.5 | 26.9 | 11.4 | 27.7 | 18.0 | 27.0 | |
| Implied Stock Price | 11,120.00 | 5,680.00 | 6,740.00 | 6,110.00 | 10,370.00 | 5,410.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 11,120.00 | 5,680.00 | 6,740.00 | 6,110.00 | 10,370.00 | 5,410.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |